NEW YORK (GenomeWeb News) – Precision BioSciences today claimed victory in a lawsuit filed against the company by Cellectis alleging patent infringement.

According to Research Triangle Park, NC-based Precision Bio, a jury in the US District Court for the District of Delaware found all claims of Cellectis' US Patent No. 7,897,372 that were asserted against Precision Bio to be invalid. The jury also found Precision Bio did not "literally" infringe the asserted claims, meaning Precision Bio did not incorporate each and every element of Cellectis' patent in its own technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The president of France's National Research Agency has resigned, according to Nature News.

A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.

In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.

The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.